Cord Blood Registry® (CBR®) and Cellular Dynamics International (NASDAQ: ICEL) (CDI) announced today that they have entered into a research collaboration to reprogram newborn stem cells from both umbilical cord blood and umbilical cord tissue collected, processed and cryopreserved under CBR’s protocols into induced pluripotent stem cells (iPSCs) using CDI’s proprietary methods. Through this research […]
Since the inception of the Wisconsin Governor’s Business Plan Contest in 2004, more than 2,900 entries have been received and about $1.8 million in cash and services have been awarded to emerging Wisconsin businesses.
Madworks Coworking‘s accelerator program, “Madworks at Campus” is offering grants to early stage startups to participate in a high energy 10-week lean startup class.
SmartUQ, a participant in the Madworks Accelerator program, raised $1.8 million in seed funding from 21 Wisconsin investors.
John Neis of Venture Investors reflects on what has been accomplished in terms of entrepreneurship in Wisconsin, and how far we still have to go to create a truly competitive entrepreneurial economy in Wisconsin.
Exact Sciences Corporation today announced the pricing of the public offering of 4,000,000 common shares priced at $25.75 per share.
The 12th annual Wisconsin Governor’s Business Plan Contest is accepting entries online for the 2015 competition until 5 p.m. Saturday, Jan. 31, 2015.
Spectrom, which developed the first device that enables Fused Deposition Modeling, or additive 3D printers, to print in full, variable color, was recently awarded first place in the undergraduate category of the Collegiate Inventors Competition.
Until now, Cellular Dynamics has been solely a provider of cells to use as research tools, but it recently took a small step toward creating a therapy with its first development deal.
Cellular Dynamics International (CDI) announced that the National Eye Institute (NEI), a division of the National Institutes of Health (NIH), awarded the company a $1.2 million contract to manufacture clinically compatible induced pluripotent stem cells (iPSCs) and iPSC-derived human retinal pigment epithelial (RPE) cells.